FDA Drug Recalls

Recalls / Class III

Class IIID-0877-2018

Product

Maxzide-25 (Triamterene and hydrochlorothiazide) tablets, USP, 37.5 mg/ 25 mg, 100-count bottle, Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV 26505, NDC 0378-0464-01

Affected lot / code info
Lot #: 3087136, Exp 5/20

Why it was recalled

Superpotent Drug: Composite assay results obtained during routine stability testing were slightly above specification.

Recalling firm

Firm
Mylan Pharmaceuticals Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
781 Chestnut Ridge Rd, N/A, Morgantown, West Virginia 26505-2730

Distribution

Quantity
1,620 bottles
Distribution pattern
Product was distributed throughout the United States

Timeline

Recall initiated
2018-06-07
FDA classified
2018-06-15
Posted by FDA
2018-06-20
Terminated
2019-06-20
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0877-2018. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class III recall: drug · FDA Drug Recalls